Pharmaceuticals

Nucleic Acid Therapeutics Industry Poised for Rapid Growth, Forecast to Touch $14.07 Billion by 2030 at 15.1% CAGR

February 17, 2026February 17, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the nucleic acid therapeutics market from 2026–2035 with trusted insights from The Business Research Company

What long-term size projections exist for the Nucleic Acid Therapeutics Market covering 2026–2035?

The nucleic acid therapeutics market has seen rapid expansion in recent years. This market is set to increase from $6.94 billion in 2025 to $8.01 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 15.4%. The historical growth has been driven by factors such as the initial limited accessibility of nucleic acid therapeutics, the reliance on traditional small molecule treatments, a rising demand for precision medicine, regulatory approvals for early gene therapies, and escalating academic investigation into gene modulation.

The nucleic acid therapeutics market is anticipated to show considerable expansion in the coming years, reaching $14.07 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 15.1%. This expected growth throughout the forecast period can be attributed to several factors, including the advancement of crispr and other gene editing technologies, the wider deployment of lipid nanoparticle (lnp) delivery systems, the increasing adoption of personalized nucleic acid therapies, a rise in partnerships between pharmaceutical and biotech companies, and growing financial input into rna-based treatments. Significant trends during this period are projected to include the increased utilization of antisense oligonucleotides (asos) and sirna therapies, the broader application of crispr-based and gene editing therapeutics, an uptick in targeted therapies for neuromuscular, metabolic, and oncological disorders, increased capital expenditure in non-viral and viral delivery systems, and the introduction of long non-coding rna (lncrna) and microrna (mirna) therapeutics.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27368&type=smp

Which Drivers Are Impacting The Competitive Landscape Of The Nucleic Acid Therapeutics Market?

The rising prevalence of genetic and chronic conditions is anticipated to fuel the expansion of the nucleic acid therapeutics market in the future. These diseases signify the link between inherited genetic elements and the onset, advancement, or susceptibility to persistent health issues like diabetes, cardiovascular diseases, cancer, and autoimmune disorders. The growth in genetics-related and chronic illnesses is primarily attributable to enhanced diagnostic methods that allow for more precise and earlier identification of these ailments. Nucleic acid therapeutics prove beneficial for genetic and chronic diseases as they can target and alter the fundamental genetic origins of these ailments through the regulation, repair, or silencing of particular genes, thereby providing accurate and tailored treatment solutions. For example, in October 2024, data from the Cystic Fibrosis Trust, a UK-based charity supporting individuals with cystic fibrosis, indicated that 11,148 cystic fibrosis patients were registered in 2022, a figure that climbed to 11,318 in 2023, showing a 1.5% year-over-year increase in patient registrations. Consequently, the expanding occurrence of genetic and chronic diseases is propelling the growth of the nucleic acid therapeutics market.

What Leading Segments Are Studied In The Nucleic Acid Therapeutics Market?

The nucleic acid therapeutics market covered in this report is segmented –

1) By Therapy Type: Antisense Oligonucleotides (ASOs), Small Interfering RNA (siRNA), Gene Therapies, Aptamers, Other Therapy Types

2) By Therapeutic Area: Neuromuscular Disorder, Metabolic Disorders, Cardiovascular Disorders, Ophthalmological Disorders, Oncological Disorders, Other Therapeutic Areas

3) By Route Of Administration: Intravenous, Subcutaneous, Other Route Of Administrations

4) By Delivery Method: Viral Vector-Based Delivery Systems, Non-Viral Delivery Systems

5) By End-Use: Pharmaceutical Companies, Government And Academic Research Institutes, Biotech Companies

Subsegments:

1) By Antisense Oligonucleotides (ASOs): Phosphorothioate ASOs, 2’-O-Methyl ASOs, Locked Nucleic Acid (LNA) ASOs, Gapmer ASOs, Morpholino ASOs

2) By Small Interfering RNA (siRNA): Lipid Nanoparticle (LNP) Formulated siRNA, GalNAc-Conjugated siRNA, Chemically Modified siRNA, Naked siRNA

3) By Gene Therapies: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, CRISPR-Based Gene Therapy, Zinc Finger Nucleases (ZFNs), TALENs

4) By Aptamers: Ribonucleic Acid (RNA) Aptamers, Deoxyribonucleic Acid (DNA) Aptamers, Spiegelmers, Pegylated Aptamers

5) By Others Therapy Types: MicroRNA (miRNA) Therapeutics, Long Non-Coding RNA (lncRNA) Therapeutics, Ribonucleic Acid (RNA) Editing Therapies, Ribozymes

What Trends Are Driving The Growth Trajectory Of The Nucleic Acid Therapeutics Market?

Major companies in the nucleic acid therapeutics market are concentrating on developing innovative products like antisense oligonucleotide therapy, which aims to target and silence specific disease-causing genes, thus providing precise treatment solutions for genetic disorders and rare diseases. Antisense oligonucleotide therapy functions as a precision treatment employing short, synthetic strands of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) to either block or modify the expression of particular genes involved in illness. For example, in December 2024, Ionis Pharmaceuticals Inc., a US-based biotechnology company, secured U.S. Food and Drug Administration (FDA) approval for TRYNGOLZ (olezarsen) as an adjunct therapy to diet for lowering triglyceride levels in adults diagnosed with familial chylomicronemia syndrome (FCS), a rare genetic condition characterized by severe hypertriglyceridemia (sHTG) and a high risk of acute pancreatitis (AP). This marks the first FDA-approved treatment to deliver significant and sustained triglyceride reduction in this patient population, alongside a clinically meaningful decrease in AP incidence when used with a low-fat diet. The therapy is designed for convenient self-administration via a once-monthly auto-injector.

Which Key Players Are Driving Competition In The Nucleic Acid Therapeutics Market?

Major companies operating in the nucleic acid therapeutics market are Pfizer Inc., Novartis AG, Moderna Inc., BioNTech SE, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., CureVac SE, Sangamo Therapeutics Inc., Beam Therapeutics Inc., Arbutus Biopharma Corporation, Silence Therapeutics plc, Copernicus Therapeutics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/nucleic-acid-therapeutics-global-market-report

Which Region Is Projected To Lead The Nucleic Acid Therapeutics Market During The Forecast Period?

North America was the largest region in the nucleic acid therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nucleic acid therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Nucleic Acid Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27368&type=smp

Browse Through More Reports Similar to the Global Nucleic Acid Therapeutics Market 2026, By The Business Research Company

Sandwich Panels Market Report 2026

https://www.thebusinessresearchcompany.com/report/sandwich-panels-global-market-report

Structural Insulated Panels Market 2026

https://www.thebusinessresearchcompany.com/report/structural-insulated-panels-market

Metal Structural Insulation Panels Market Report 2026

https://www.thebusinessresearchcompany.com/report/metal-structural-insulation-panels-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795